ARTICLE | Product Development

FDA approval sets up BMS’s Sotyktu as oral therapy of choice in psoriasis

Deucravacitinib safety, near biologic-like efficacy position first-in-class TYK2 inhibitor to supplant Otezla

September 10, 2022 4:19 PM UTC
Updated on Sep 13, 2022 at 12:15 AM UTC

Strong efficacy data and a clean label put Bristol Myers’ Sotyktu deucravacitinib in pole position to quickly become the oral standard of care for plaque psoriasis.

Late Friday, FDA approved the first-in-class TYK2 inhibitor to treat moderate-to-severe plaque psoriasis, making it the second oral therapy approved for the indication after Otezla apremilast. ...

BCIQ Company Profiles

Bristol Myers Squibb Co.

BCIQ Target Profiles

Tyrosine kinase 2 (TYK2)